Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma

Angiogenesis in general and the vascular endothelial growth factor (VEGF) signaling axis in particular is a validated target in renal cell carcinoma (RCC). Clear-cell carcinoma of the kidney is now recognized as a malignancy that is sensitive to inhibitors of the VEGF pathway. Treatment options for...

Descripción completa

Detalles Bibliográficos
Autor principal: Bukowski, Ronald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356077/
https://www.ncbi.nlm.nih.gov/pubmed/22655261
http://dx.doi.org/10.3389/fonc.2012.00013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356077/
https://www.ncbi.nlm.nih.gov/pubmed/22655261
http://dx.doi.org/10.3389/fonc.2012.00013

Ejemplares similares